Volume 17, Issue 55 (3-2017)                   Zanko J Med Sci 2017, 17(55): 46-54 | Back to browse issues page

XML Persian Abstract Print


Kurdistan University of Medical Sciences
Abstract:   (3439 Views)

Backgrounds and Aim: Infection with hepatitis B is one of the most major problems in the global health and Iran. Since hemodialysis patients are exposing to blood products repeatedly so their contact with hepatitis virus more likely too, by this they may not have suitable response to hepatitis B vaccine. The aim of this study was to investigate HbsAb titer and hepatitis B vaccine efficiency in Hemodialysis patients hospitalized in Salahedin Ayobi and Emam Khomeini hospitals in Bane and Saqez cities.

Material and Methods: In this cross - sectional study, total of 133 Hemodialysis patients in Salahedin Ayobi and Emam Khomeini hospitals in Bane and Saqez cities in 2014 were examined. Patient's Information was gathered and recorded from their documents by a check list. Data were performed by using SPSS ver.18 software and were analyzed by t-test and K-square's tests.

Results: The mean age of patients was 60.23 years and the mean of HbsAb level was 93.22. About 70.1 % of patients had vaccination history. Comparing the HbsAb titer in two age groups (≤40 and >40) was not significant. (P= 0.7). There was not statistical significant difference in diabetic compared with non diabetic patients (P=0.4) and in both male and female too (P= 0.77). A statistical significant relationship was found between HbsAb and vaccination history (P= 0.02).

Conclusion: Based on our findings, vaccinated patients were at a lower risk of infection with hepatitis B, Thus vaccination is recommended for those who have not been vaccinated by hepatitis B during their life.

Full-Text [PDF 769 kb]   (2256 Downloads)    
Type of Study: Research | Subject: General
Received: 2016/11/23 | Accepted: 2016/12/21 | ePublished: 2017/04/18

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.